Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547231 | 0.86 | CTSL (0.51) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL13547182 | 0.82 | SMN1; SMN2 (0.52) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL13547180 | 0.82 | SMN1; SMN2 (0.52) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL3616970 | 0.82 | SMN1; SMN2 (0.51) | MEN1KMT2AALDH1A1GAATSHR | |
| SCHEMBL13547236 | 0.82 | MEN1 (0.56) | MEN1KMT2AGPR55CTSLCTSB | |
| SCHEMBL3602821 | 0.81 | SMN1; SMN2 (0.51) | MEN1KMT2AALDH1A1GAAHSD11B1 | |
| SCHEMBL3616214 | 0.80 | DPP4 (0.51) | MEN1KMT2AALDH1A1GAATSHR | |
| SCHEMBL13547234 | 0.79 | ALDH1A1 (0.60) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL13547235 | 0.78 | HSD11B1 (0.48) | MEN1KMT2AGPR55ALDH1A1GAA | |
| SCHEMBL13547219 | 0.74 | MEN1 (0.52) | MEN1KMT2AGPR55ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| WO-2008039420-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, SI, MGAM2 | MEN1 3480/4885KMT2A 1484/4885GPR55 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.